{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:08:38Z","timestamp":1790662118662,"version":"4.1.0"},"reference-count":100,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Telethon - Italy","award":["GGP12108"],"award-info":[{"award-number":["GGP12108"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fabry disease is caused by mutations in the GLA gene and is characterized by a large genotypic and phenotypic spectrum. Missense mutations pose a special problem for graduating diagnosis and choosing a cost-effective therapy. Some mutants retain enzymatic activity, but are less stable than the wild type protein. These mutants can be stabilized by small molecules which are defined as pharmacological chaperones. The first chaperone to reach clinical trial is 1-deoxygalactonojirimycin, but others have been tested in vitro. Residual activity of GLA mutants has been measured in the presence or absence of pharmacological chaperones by several authors. Data obtained from transfected cells correlate with those obtained in cells derived from patients, regardless of whether 1-deoxygalactonojirimycin was present or not. The extent to which missense mutations respond to 1-deoxygalactonojirimycin is variable and a reference table of the results obtained by independent groups that is provided with this paper can facilitate the choice of eligible patients. A review of other pharmacological chaperones is provided as well. Frequent mutations can have residual activity as low as one-fourth of normal enzyme in vitro. The reference table with residual activity of the mutants facilitates the identification of non-pathological variants.<\/jats:p>","DOI":"10.3390\/ijms17122010","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T10:36:37Z","timestamp":1480674997000},"page":"2010","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations"],"prefix":"10.3390","volume":"17","author":[{"given":"Valentina","family":"Citro","sequence":"first","affiliation":[{"name":"Dipartimento di Biologia, Universit\u00e0 Federico II, 80126 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cammisa","sequence":"additional","affiliation":[{"name":"Istituto di Genetica e Biofisica \u2018A. Buzzati-Traverso\u2019, CNR, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-0501","authenticated-orcid":false,"given":"Ludovica","family":"Liguori","sequence":"additional","affiliation":[{"name":"Istituto di Chimica Biomolecolare, CNR, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cimmaruta","sequence":"additional","affiliation":[{"name":"Dipartimento di Biologia, Universit\u00e0 Federico II, 80126 Napoli, Italy"},{"name":"Istituto di Chimica Biomolecolare, CNR, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lukas","sequence":"additional","affiliation":[{"name":"Albrecht-Kossel-Institute for Neuroregeneration, University Rostock Medical Center, 18147 Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-6553","authenticated-orcid":false,"given":"Maria","family":"Cubellis","sequence":"additional","affiliation":[{"name":"Dipartimento di Biologia, Universit\u00e0 Federico II, 80126 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-0156","authenticated-orcid":false,"given":"Giuseppina","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Istituto di Chimica Biomolecolare, CNR, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/8904_2015_435","article-title":"The frequencies of different inborn errors of metabolism in adult metabolic centres: Report from the ssiem adult metabolic physicians group","volume":"27","author":"Sirrs","year":"2016","journal-title":"JIMD Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lukas, J., Giese, A.K., Markoff, A., Grittner, U., Kolodny, E., Mascher, H., Lackner, K.J., Meyer, W., Wree, P., and Saviouk, V. (2013). Functional characterisation of \u03b1-galactosidase a mutations as a basis for a new classification system in Fabry disease. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003632"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.5414\/CNP75506","article-title":"Fabry disease: Results of the first UK hemodialysis screening study","volume":"75","author":"Wallin","year":"2011","journal-title":"Clin. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/jhg.2012.68","article-title":"High-throughput screening identified disease-causing mutants and functional variants of \u03b1-galactosidase a gene in japanese male hemodialysis patients","volume":"57","author":"Doi","year":"2012","journal-title":"J. Hum. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/STROKEAHA.112.663708","article-title":"Acute cerebrovascular disease in the young: The stroke in young Fabry patients study","volume":"44","author":"Rolfs","year":"2013","journal-title":"Stroke"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in taiwan reveals a high incidence of the later-onset GLA mutation C.936 + 919G > A (IVS4 + 919G > A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ymgme.2014.11.005","article-title":"Absence of \u03b1-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts","volume":"114","author":"Fuller","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-4-21","article-title":"Fabry disease: Recent advances in pathology, diagnosis, treatment and monitoring","volume":"4","author":"Hoffmann","year":"2009","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"Taguchi","year":"2013","journal-title":"Biochem. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.3892\/mmr.2015.4010","article-title":"Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease","volume":"12","author":"Shin","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","article-title":"Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"515","author":"Mills","year":"2002","journal-title":"FEBS Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Cyr","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"ref_20","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2006). Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis."},{"key":"ref_21","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2006). Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis."},{"key":"ref_22","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2006). Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The mainz severity score index: A new instrument for quantifying the anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","article-title":"A validated disease severity scoring system for Fabry disease","volume":"99","author":"Giannini","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ckj\/sfw082","article-title":"Fabry stabilization index (fastex): An innovative tool for the assessment of clinical stabilization in Fabry disease","volume":"9","author":"Mignani","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10709-008-9245-y","article-title":"Genetic polymorphisms of vitamin D receptor (VDR) in Fabry disease","volume":"134","author":"Teitcher","year":"2008","journal-title":"Genetica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu","year":"2005","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The european Fabry working group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-\u03b2 therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: A systematic review and meta-analysis: Effectiveness of ert in different disease stages","volume":"37","author":"Rombach","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase \u03b2 therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: Effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","article-title":"Central nervous system involvement in anderson-Fabry disease: A clinical and MRI retrospective study","volume":"79","author":"Buechner","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","article-title":"Cns involvement in Fabry disease: Clinical and imaging studies before and after 12 months of enzyme replacement therapy","volume":"27","author":"Jardim","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1590\/S0004-282X2006000500002","article-title":"White matter lesions in Fabry disease before and after enzyme replacement therapy: A 2-year follow-up","volume":"64","author":"Jardim","year":"2006","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: Evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beem.2014.08.006","article-title":"The attenuated\/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in gaucher and Fabry disease","volume":"29","author":"Hollak","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/dta.1798","article-title":"Looking for protein stabilizing drugs with thermal shift assay","volume":"7","author":"Andreotti","year":"2015","journal-title":"Drug Test. Anal."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.bbagen.2013.12.018","article-title":"A thermodynamic assay to test pharmacological chaperones for Fabry disease","volume":"1840","author":"Andreotti","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase a tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Warnock, D.G., Bichet, D.G., Holida, M., Goker-Alpan, O., Nicholls, K., Thomas, M., Eyskens, F., Shankar, S., Adera, M., and Sitaraman, S. (2015). Oral migalastat HCL leads to greater systemic exposure and tissue levels of active \u03b1-galactosidase a in Fabry patients when co-administered with infused agalsidase. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134341"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/mt.2015.87","article-title":"Coformulation of a novel human \u03b1-galactosidase a with the pharmacological chaperone AT1001 leads to improved substrate reduction in Fabry mice","volume":"23","author":"Xu","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Young-Gqamana, B., Brignol, N., Chang, H.H., Khanna, R., Soska, R., Fuller, M., Sitaraman, S.A., Germain, D.P., Giugliani, R., and Hughes, D.A. (2013). Migalastat hcl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057631"},{"key":"ref_48","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: In vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/abbi.2000.1743","article-title":"Role of ser-65 in the activity of \u03b1-galactosidase a: Characterization of a point mutation (S65T) detected in a patient with Fabry disease","volume":"377","author":"Ishii","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in Fabry disease","volume":"359","author":"Shin","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant \u03b1-galactosidase a enzymes identified in Fabry disease patients with residual enzyme activity: Biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/FPC.0b013e32830500f4","article-title":"Prediction of response of mutated \u03b1-galactosidase a to a pharmacological chaperone","volume":"18","author":"Shin","year":"2008","journal-title":"Pharmacogenet. Genom."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3858\/emm.2009.41.1.001","article-title":"Effects of a chemical chaperone on genetic mutations in \u03b1-galactosidase a in Korean patients with Fabry disease","volume":"41","author":"Park","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase a levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbadis.2009.11.003","article-title":"Functional studies of new GLA gene mutations leading to conformational Fabry disease","volume":"1802","author":"Filoni","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase a that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum. Mutat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1750-1172-6-66","article-title":"Therapy of Fabry disease with pharmacological chaperones: From in silico predictions to in vitro tests","volume":"6","author":"Andreotti","year":"2011","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","article-title":"A phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects","volume":"109","author":"Giugliani","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/humu.22910","article-title":"Functional and clinical consequences of novel \u03b1-galactosidase a mutations in Fabry disease","volume":"37","author":"Lukas","year":"2016","journal-title":"Hum. Mutat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpdd.1","article-title":"Pharmacokinetics and safety of migalastat HCL and effects on agalsidase activity in healthy volunteers","volume":"2","author":"Johnson","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ymgme.2012.01.010","article-title":"Fabry disease: Biochemical, pathological and structural studies of the \u03b1-galactosidase a with E66Q amino acid substitution","volume":"105","author":"Togawa","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Benjamin, E.R., Della Valle, M.C., Wu, X., Katz, E., Pruthi, F., Bond, S., Bronfin, B., Williams, H., Yu, J., and Bichet, D.G. (2016). The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet. Med.","DOI":"10.1038\/gim.2016.122"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biochi.2015.03.018","article-title":"Taming molecular flexibility to tackle rare diseases","volume":"113","author":"Cubellis","year":"2015","journal-title":"Biochimie"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/jhg.2010.5","article-title":"Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information","volume":"55","author":"Saito","year":"2010","journal-title":"J. Hum. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/prot.24708","article-title":"Molecular damage in Fabry disease: Characterization and prediction of \u03b1-galactosidase a pathological mutations","volume":"83","author":"Riera","year":"2015","journal-title":"Proteins"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00207037","article-title":"Point mutations in the upstream region of the \u03b1-galactosidase a gene exon 6 in an atypical variant of Fabry disease","volume":"89","author":"Ishii","year":"1992","journal-title":"Hum. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/eurjhf\/hfq073","article-title":"Fabry disease mimicking hypertrophic cardiomyopathy: Genetic screening needed for establishing the diagnosis in women","volume":"12","author":"Havndrup","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of \u03b1-galactosidase a activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"ref_71","first-page":"1186","article-title":"Nature and frequency of mutations in the \u03b1-galactosidase a gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1096-7192(02)00012-4","article-title":"Fabry disease: 45 novel mutations in the \u03b1-galactosidase a gene causing the classical phenotype","volume":"76","author":"Shabbeer","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The \u03b1-galactosidase a p.Arg118cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of Fabry and pompe disease","volume":"23","author":"Lukas","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","article-title":"\u03b1-Galactosidase A p.A143T, a non-Fabry disease-causing variant","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.gene.2015.09.088","article-title":"GLA variation p.E66Q identified as the genetic etiology of Fabry disease using exome sequencing","volume":"575","author":"Peng","year":"2016","journal-title":"Gene"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Oikawa, M., Sakamoto, N., Kobayashi, A., Suzuki, S., Yoshihisa, A., Yamaki, T., Nakazato, K., Suzuki, H., Saitoh, S., and Kiko, Y. (2016). Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body. BMC Cardiovasc. Disord., 16.","DOI":"10.1186\/s12872-016-0262-y"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ene.12214","article-title":"P.E66Q mutation in the GLA gene is associated with a high risk of cerebral small-vessel occlusion in elderly Japanese males","volume":"21","author":"Nakamura","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1111\/ene.12459","article-title":"Comment on \u2018p.E66q mutation in the GLA gene is associated with a high risk of cerebral small-vessel occlusion in elderly japanese males\u2019","volume":"21","author":"Satomura","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/humu.9520","article-title":"Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone","volume":"29","author":"Shimotori","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2012_154","article-title":"Lyso-Gb3 indicates that the \u03b1-galactosidase a mutation D313Y is not clinically relevant for Fabry disease","volume":"7","author":"Niemann","year":"2013","journal-title":"JIMD Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cge.12261","article-title":"Intrafamilial phenotypic variability in four families with anderson-Fabry disease","volume":"86","author":"Rigoldi","year":"2014","journal-title":"Clin. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1042\/bj3320789","article-title":"Human \u03b1-galactosidase A: Glycosylation site 3 is essential for enzyme solubility","volume":"332","author":"Ioannou","year":"1998","journal-title":"Biochem. J."},{"key":"ref_84","first-page":"S113","article-title":"The N215S mutation results in a distinct subtype of Fabry disease","volume":"114","author":"Thomas","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2003.09.022","article-title":"Fabry disease: Renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications","volume":"43","author":"Meehan","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1006\/bbrc.1995.2416","article-title":"Galactose stabilizes various missense mutants of \u03b1-galactosidase in Fabry disease","volume":"214","author":"Okumiya","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human \u03b1-galactosidase A: Pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1016\/j.bmc.2010.04.048","article-title":"2,5-dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease","volume":"18","author":"Kato","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1021\/jo301243s","article-title":"Glycosidase inhibition by all 10 stereoisomeric 2,5-dideoxy-2,5-iminohexitols prepared from the enantiomers of glucuronolactone","volume":"77","author":"Ayers","year":"2012","journal-title":"J. Org. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2016.07.025","article-title":"Bioevaluation of sixteen admdp stereoisomers toward \u03b1-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency","volume":"123","author":"Cheng","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1002\/anie.201505147","article-title":"pH-responsive pharmacological chaperones for rescuing mutant glycosidases","volume":"54","author":"Narita","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1875397301004010067","article-title":"High throughput screening for inhibitors of \u03b1-galactosidase","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genom."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Citro, V., Pe\u00f1a-Garc\u00eda, J., den-Haan, H., P\u00e9rez-S\u00e1nchez, H., del Prete, R., Liguori, L., Cimmaruta, C., Lukas, J., Cubellis, M.V., and Andreotti, G. (2016). Identification of an allosteric binding site on human lysosomal \u03b1-galactosidase opens the way to new pharmacological chaperones for Fabry disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165463"},{"key":"ref_96","unstructured":"Linear Correlation and Regression. Available online: http:\/\/vassarstats.net\/corr_big.html."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1172-5-36","article-title":"Prediction of the responsiveness to pharmacological chaperones: Lysosomal human \u03b1-galactosidase, a case of study","volume":"5","author":"Andreotti","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1750-1172-8-111","article-title":"Fabry_cep: A tool to identify Fabry mutations responsive to pharmacological chaperones","volume":"8","author":"Cammisa","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Cammisa, M., Correra, A., Andreotti, G., and Cubellis, M.V. (2013). Identification and analysis of conserved pockets on protein surfaces. BMC Bioinform., 14.","DOI":"10.1186\/1471-2105-14-S7-S9"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat. Methods"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/12\/2010\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:27:49Z","timestamp":1760210869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/12\/2010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":100,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["ijms17122010"],"URL":"https:\/\/doi.org\/10.3390\/ijms17122010","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}